Is there a study showing ketamine cures ME/CFS?

No. There is no randomized controlled trial in a pure ME/CFS population, and we would not use the word cure for any condition. The supporting evidence is indirect, drawn from depression-with-fatigue research, fibromyalgia studies, and the central-sensitization mechanism. We treat that as a clinical hypothesis worth discussing, not a proven indication.

Will ketamine fix post-exertional malaise?

Unknown. Post-exertional malaise is the cardinal feature of ME/CFS, and we will not promise that ketamine resolves it. Some patients report a higher energy floor after a series of infusions; others see no change. Anyone considering ketamine for ME/CFS should talk to their specialist about pacing and how to monitor PEM in the days after each session.

What about long-COVID fatigue?

Long-COVID and ME/CFS overlap heavily in their diagnostic criteria, and many long-COVID patients eventually meet ME/CFS thresholds. The same caveats apply: there is no large RCT for ketamine in either condition. Our companion article on ketamine for long-COVID neuropsychiatric symptoms walks through what the early signal looks like and where it stops.

If I have ME/CFS plus depression, am I a candidate?

More likely yes, because the depression piece has real evidence behind it. In that scenario we would treat the depression as the primary target, follow standard mental-wellness protocols, and watch fatigue as a secondary outcome rather than promising it will improve. Your ME/CFS specialist should still be in the loop on dosing decisions and pacing.

Could ketamine make ME/CFS worse?

Honestly, we do not know. PEM-style crashes after the dissociative session are theoretically possible, especially if a patient pushes activity too soon afterward. We mitigate that with conservative dosing, anesthesia-level monitoring during the infusion, an unhurried recovery, and explicit pacing guidance for the days that follow. We always defer to the patient's ME/CFS specialist on activity tolerance.

Ketamine for chronic fatigue syndrome and ME/CFS: what the evidence actually says

What ME/CFS actually is (and isn't)

Myalgic encephalomyelitis / chronic fatigue syndrome is a serious, chronic, complex multisystem disease. The U.S. National Institute of Neurological Disorders and Stroke describes it that way in its 2024 ME/CFS overview, and the National Academy of Medicine has used similar language since 2015. It is not a synonym for being tired. The cardinal feature is post-exertional malaise — a disproportionate, often delayed crash after physical, cognitive, or emotional effort — layered on top of unrefreshing sleep, orthostatic intolerance, and cognitive dysfunction.

That distinction matters here because most people who write about “chronic fatigue” online are actually writing about generalized fatigue, burnout, or depression with prominent anhedonia. Those conditions overlap with ME/CFS but are not the same thing, and they respond to different treatments. Before any conversation about ketamine, the diagnosis itself should be settled by a clinician who works with this patient population.

NIH-funded researchers and the Centers for Disease Control estimate that between 836,000 and 2.5 million Americans live with ME/CFS, and the majority remain undiagnosed. Long-COVID has expanded that pool considerably; a substantial fraction of long-COVID patients eventually meet ME/CFS criteria, which is why the two conditions now share much of the same research literature.

Why ketamine even comes up — central sensitization and the depression overlap

Two threads bring ketamine into the ME/CFS conversation, and neither is a direct one.

The first is mechanistic. ME/CFS shares features of central sensitization with fibromyalgia — a state in which the central nervous system amplifies sensory and pain signals through glutamate-driven hyperexcitability at the NMDA receptor. Clinical reviews of NMDA-antagonist therapy in central-sensitization conditions, tracked publicly through Health Rising’s 2015 review of ketamine in this space, lay out the rationale: if NMDA hyperactivity is part of the problem, an NMDA antagonist is at least mechanistically plausible. The fibromyalgia evidence is much stronger than the ME/CFS evidence, but the underlying biology rhymes.

The second thread is the depression overlap. Depression and anxiety co-occur with ME/CFS at high rates — a reasonable estimate is that roughly half of ME/CFS patients meet criteria for a depressive or anxiety disorder at some point in their illness, often as a downstream consequence of chronic disability rather than a cause of it. Ketamine has a meaningful evidence base for treatment-resistant depression, and that is where most of the real clinical signal lives.

Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, and any pain or fatigue indication is off-label. The Spravato (esketamine) nasal spray is the only ketamine-related product the FDA has approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Any conversation about ketamine for ME/CFS sits firmly in off-label territory.

What the research actually shows

Three pieces of literature carry most of the weight here, and they should be read carefully because what they show is narrower than what the headlines suggest.

Saligan and colleagues (2016), Journal of Affective Disorders. A placebo-controlled crossover trial in patients with bipolar depression looked specifically at fatigue as an outcome. Fatigue scores dropped within hours of a single ketamine infusion, and the anti-fatigue effect was statistically separable from the overall antidepressant effect. That detail matters: it suggests ketamine has a mechanism that touches fatigue circuitry, not just mood. It does not show that this mechanism translates to ME/CFS, which the study did not examine.

U.S. NIH / NINDS (2024) ME/CFS overview. NINDS recognizes ME/CFS as a serious, chronic, complex multisystem disease and explicitly notes the diagnostic overlap between ME/CFS and long-COVID. It does not endorse any specific pharmacologic treatment; the document is candid that disease-modifying therapies remain an unmet research need.

The Health Rising clinical review (2015). This review makes the mechanistic case for trialing NMDA antagonists in central-sensitization conditions, including fibromyalgia and ME/CFS. It also states plainly that pure-ME/CFS randomized controlled trials of ketamine remain absent. The body of evidence in ME/CFS itself consists of case reports, small open-label series, and inference from adjacent conditions.

A systematic search through the 2020s does not change this picture. Studies of ketamine for treatment-resistant depression, complex regional pain syndrome, and fibromyalgia continue to accumulate; well-designed ME/CFS-specific ketamine trials do not. The honest summary is that we have a hypothesis, an analogous condition (fibromyalgia) where the data is reasonably good, and a related symptom (depression-with-fatigue) where the data is good. We do not have direct evidence in ME/CFS.

Long-COVID and post-viral fatigue — the new overlap

Long-COVID has reshaped the ME/CFS conversation. A meaningful subset of long-COVID patients meet ME/CFS diagnostic criteria, and the symptom clusters — post-exertional malaise, brain fog, orthostatic intolerance, sleep dysfunction — are nearly indistinguishable. Our long-COVID neuropsychiatric article covers the early ketamine signal in that population in more depth, and most of what is true there is also true for ME/CFS: the depression and anxiety components have the most plausible response, the fatigue and PEM components are far less certain, and the absence of large RCTs means everything is provisional.

That said, the long-COVID research wave is the most likely source of better ME/CFS data over the next several years. Trials currently enrolling for long-COVID fatigue may, indirectly, give us our first credible read on whether ketamine moves the post-viral-fatigue needle.

Where ketamine probably won’t help in ME/CFS

We want to be straight about what this treatment is not, especially in a population that has often been promised more than medicine can deliver.

Post-exertional malaise. There is no good evidence ketamine resolves PEM. Pacing, energy envelope work, and disease-specific specialist care remain the foundation.
Orthostatic intolerance and POTS. Autonomic dysfunction is its own physiology and has its own treatment ladder. Ketamine is not part of it.
Sleep architecture. Ketamine can affect sleep in either direction in the short term and is not a sleep treatment for ME/CFS.
Immune and metabolic abnormalities. The biomarker-level dysfunction in ME/CFS is not what ketamine is acting on, even in the depression context.

Said simply: ketamine, in this disease, is best understood as a possible tool for treating the depression and anxiety that often co-occur with ME/CFS, not ME/CFS itself. That framing keeps everyone honest.

What an honest conversation looks like

A reasonable consultation for an ME/CFS patient who is also struggling with depression will sound roughly like this. We will review the diagnosis and confirm an ME/CFS specialist is involved. We will ask whether depression and anxiety are part of the picture — distinguishing burnout from clinical depression matters, because they respond differently. We will set the depression as the primary outcome we are tracking and treat any fatigue improvement as a secondary observation, not a promise.

If you decide to proceed, sessions follow our standard mental-wellness protocol with two ME/CFS-specific adjustments: a more conservative starting dose with slower titration, and explicit pacing guidance for the 72 hours after each session. Marla Peterson, CRNA, oversees every infusion and provides anesthesia-level monitoring — continuous pulse oximetry, blood pressure, and heart-rate tracking — with a CRNA in the room. We do not rush recovery, and we ask patients to plan a full rest day after every session, not just the day of the infusion.

Cost is transparent: at Music City Ketamine, sessions are $475 each, and insurance generally does not cover ketamine for ME/CFS. We will say so up front. If a course of treatment doesn’t make sense for your situation, we will tell you that too.

Talking to your ME/CFS specialist before booking ketamine

This is the part of the article we want underlined. Before you schedule anything, talk to your ME/CFS specialist. They know your PEM threshold, your medication landscape, and any orthostatic issues that change how dissociation and recovery should be managed. They can also help you decide whether the depression-and-anxiety target is the right primary indication, or whether your situation calls for depression-specific treatment first or a chronic-pain track if widespread pain is dominant.

If you take medications that interact with ketamine — certain benzodiazepines, lamotrigine, monoamine modulators — that is another conversation for your prescribing provider. Never start, stop, or change medications on your own. The point of a coordinated approach is to keep the people who already know your case in the loop.

Where the literature supports a careful trial, we are happy to be one option. Where it doesn’t, we will say so. If you want to read further on the underlying neuroscience, our piece on how ketamine acts on the brain and our overview of how ketamine works mechanistically are good companions to this article. ME/CFS deserves serious medicine and serious caution, and we’d rather give you both than oversell either.